PMID- 1940193
OWN - NLM
STAT- MEDLINE
DCOM- 19911129
LR  - 20190817
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 13 Suppl 1
DP  - 1991
TI  - Assessment of mucus glycoprotein erosion by measurement of sialic acid in gastric 
      secretions: pathophysiologic and therapeutic aspects.
PG  - S22-31
AB  - The quantification of mucus glycoproteins (GPs) faces paramount difficulties in 
      terms of methods and interpretation. Mucus glycoprotein erosion, however, might 
      be quantified in gastric juice by measurement of GP-bound sialic acid. Basal 
      sialic acid content was low in normal healthy subjects (N) and in nonulcer 
      dyspepsia (NUD) patients. They were five to six times higher in duodenal ulcer 
      (DU), or more in Zollinger-Ellison patients. Pentagastrin stimulation induced a 
      five- to sixfold rise in N and NUD patients although it did not affect DU patient 
      sialic acid contents. Relationships between sialic acid content and pepsin output 
      in DU indicate that pepsin exerts a variable mucolytic activity depending on 
      disease evolution. In addition to pepsin, duodenogastric reflux exerts a potent 
      mucolytic effect. Therapeutically, highly selective vagotomy without recurrent 
      ulcer markedly reduced mucus erosion. The reduction of mucus erosion by 
      protective drugs has been observed in some cases but in other cases sialic acid 
      measurement did not allow to verify a protective effect. Adherent mucus analysis 
      by high-performance liquid chromatography (HPLC) should allow one to appreciate 
      GP fractions qualitatively. Combination of both methods should allow further 
      determination of the mucus protective role, simultaneously investigating the 
      adherent mucus quality and eroded GPs.
FAU - Pasquier, M C
AU  - Pasquier MC
AD  - INSERM U 10, C.H.U. Xavier Bichat, Paris, France.
FAU - Vatier, J
AU  - Vatier J
FAU - Poitevin, C
AU  - Poitevin C
FAU - Vallot, T
AU  - Vallot T
FAU - Mignon, M
AU  - Mignon M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (Aluminum Compounds)
RN  - 0 (Antacids)
RN  - 0 (Glycoproteins)
RN  - 0 (Phosphates)
RN  - 0 (Sialic Acids)
RN  - CPD4NFA903 (Aluminum)
RN  - EC 3.4.23.1 (Pepsin A)
RN  - EF0NX91490 (Pentagastrin)
RN  - F92V3S521O (aluminum phosphate)
RN  - GZP2782OP0 (N-Acetylneuraminic Acid)
SB  - IM
MH  - Aluminum/therapeutic use
MH  - *Aluminum Compounds
MH  - Antacids/therapeutic use
MH  - Duodenal Ulcer/physiopathology/therapy
MH  - Dyspepsia/physiopathology
MH  - Gastric Juice/*chemistry/metabolism
MH  - Gastric Mucosa/*metabolism
MH  - Glycoproteins/chemistry/*metabolism
MH  - Humans
MH  - N-Acetylneuraminic Acid
MH  - Pentagastrin
MH  - Pepsin A/metabolism
MH  - Phosphates/therapeutic use
MH  - Sialic Acids/*analysis
MH  - Vagotomy, Proximal Gastric
MH  - Zollinger-Ellison Syndrome/physiopathology
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1097/00004836-199112001-00004 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 1991;13 Suppl 1:S22-31. doi: 
      10.1097/00004836-199112001-00004.